Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Meanwhile, 3SBio is gearing up to initiate the first Phase 3 study in China in 2025. Pfizer Oncology, known for its extensive portfolio and pipeline, aims to deliver transformative therapies for ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of China. As well as securing record sums in upfront and other fees, the ...

Pfizer also has an option to obtain commercialization rights in China. Separately, Pfizer said it plans to invest $100 million in 3SBio equity after the licensing deal closes, which is expected in the ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

PD-1/VEGF bispecifics are becoming too important to ignore, and the 3SBio deal is a very cheap way to participate And while some may criticize Pfizer for a lack of imagination, I like this deal ...